Finance

Lists
NOVA:FRA
Նովո Նորդիսկ
33,02 €
-1,61%
(-0,54) 1D
2 հոկ, 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOVA...
Open
33,08 €
High
33,34 €
Low
33,02 €
Mkt. cap
128,18 մլրդ
Avg. vol.
1,29 հզր
Volume
924,00
52-wk high
54,80 €
52-wk low
30,45 €
No. of employees
67 հզր
Open
33,08 €
High
33,34 €
Low
33,02 €
Mkt. cap
128,18 մլրդ
Avg. vol.
1,29 հզր
Volume
924,00
52-wk high
54,80 €
52-wk low
30,45 €
No. of employees
67 հզր
News stories
From web sources and news partners
Profile
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds approximately 28.1% of its shares and a majority of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
About Նովո Նորդիսկ
CEOMaziar Mike Doustdar
Employees66,7 հզր
Founded21 դեկ, 1923 թ.
HeadquartersBagsværd, Մայրաքաղաքային տարածաշրջան, Դանիա
Sector-
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
74,98 մլրդ
79,14 մլրդ
96,82 մլրդ
78,49 մլրդ
Cost of goods sold
14,47 մլրդ
14,17 մլրդ
13,60 մլրդ
17,10 մլրդ
Cost of revenue
14,47 մլրդ
14,17 մլրդ
13,60 մլրդ
17,10 մլրդ
Research and development expenses
11,49 մլրդ
12,67 մլրդ
10,28 մլրդ
11,46 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15,76 մլրդ
17,14 մլրդ
13,22 մլրդ
16,31 մլրդ
Operating expense
27,25 մլրդ
29,73 մլրդ
23,61 մլրդ
28,00 մլրդ
Total operating expenses
41,72 մլրդ
43,90 մլրդ
37,20 մլրդ
45,10 մլրդ
Operating income
33,25 մլրդ
35,24 մլրդ
59,62 մլրդ
33,39 մլրդ
Other non operating income
1,53 մլրդ
-241,00 մլն
-
-
EBT including unusual items
25,52 մլրդ
34,18 մլրդ
62,17 մլրդ
26,88 մլրդ
EBT excluding unusual items
35,09 մլրդ
37,62 մլրդ
62,17 մլրդ
33,20 մլրդ
Income tax expense
5,51 մլրդ
7,29 մլրդ
13,62 մլրդ
5,89 մլրդ
Effective tax rate
21,60%
21,34%
21,90%
21,90%
Other operating expenses
-
-81,00 մլն
106,00 մլն
234,00 մլն
Net income
20,01 մլրդ
26,89 մլրդ
48,56 մլրդ
20,99 մլրդ
Net profit margin
26,68%
33,98%
50,15%
26,74%
Earnings per share
4,50
6,04
6,63
6,18
Interest and investment income
307,00 մլն
4,41 մլրդ
-
1,31 մլրդ
Interest expense
-
-4,97 մլրդ
-
-1,50 մլրդ
Net interest expenses
307,00 մլն
-560,00 մլն
-
-186,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
36,49 մլրդ
36,66 մլրդ
63,13 մլրդ
36,99 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps